- Home
- PRFX vs PBM Comparison
PRFX vs PBM Comparison
Compare PRFX & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- PBM
- Stock Information
- Founded
- PRFX 2007
- PBM 1994
- Country
- PRFX Israel
- PBM Canada
- Employees
- PRFX N/A
- PBM N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- PBM
- Sector
- PRFX Health Care
- PBM
- Exchange
- PRFX Nasdaq
- PBM NYSE
- Market Cap
- PRFX 3.6M
- PBM 3.0M
- IPO Year
- PRFX 2020
- PBM N/A
- Fundamental
- Price
- PRFX $1.39
- PBM $4.91
- Analyst Decision
- PRFX Hold
- PBM
- Analyst Count
- PRFX 1
- PBM 0
- Target Price
- PRFX N/A
- PBM N/A
- AVG Volume (30 Days)
- PRFX 185.8K
- PBM 114.1K
- Earning Date
- PRFX 08-14-2025
- PBM 07-07-2025
- Dividend Yield
- PRFX N/A
- PBM N/A
- EPS Growth
- PRFX N/A
- PBM N/A
- EPS
- PRFX N/A
- PBM 5.24
- Revenue
- PRFX N/A
- PBM N/A
- Revenue This Year
- PRFX N/A
- PBM N/A
- Revenue Next Year
- PRFX N/A
- PBM N/A
- P/E Ratio
- PRFX N/A
- PBM $0.94
- Revenue Growth
- PRFX N/A
- PBM N/A
- 52 Week Low
- PRFX $1.25
- PBM $2.93
- 52 Week High
- PRFX $16.63
- PBM $701.82
- Technical
- Relative Strength Index (RSI)
- PRFX 33.95
- PBM 53.67
- Support Level
- PRFX $1.25
- PBM $4.52
- Resistance Level
- PRFX $1.76
- PBM $5.23
- Average True Range (ATR)
- PRFX 0.10
- PBM 0.54
- MACD
- PRFX -0.05
- PBM -0.01
- Stochastic Oscillator
- PRFX 23.53
- PBM 49.93
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.